Patents Examined by Gail Poulos
  • Patent number: 5134065
    Abstract: A novel and unique plasminogen activator inhibitor fragment is obtained from human umbilical vein endothelial cells which has the following characteristics:A. it is derived from a native t-PA inhibitor that binds to and inhibits the activity of t-PA,B. it is dissociated from a complex formed between said native t-PA inhibitor and t-PA, said complex existing in two distinct interconvertible conformations with molecular weight of about 88 KDa and 105 KDa, respectively, and being partially reversible in the presence of fibrin,C. it has a molecular weight of about 40 KDa when dissociated from the complex, andD. it has a novel partial N-terminal amino acid sequence when dissociated from the complex.
    Type: Grant
    Filed: May 16, 1986
    Date of Patent: July 28, 1992
    Assignee: Monsanto Company
    Inventors: Michael A. Sanzo, Arthur J. Wittwer, Jayne C. Marasa, Joseph Feder
  • Patent number: 5132214
    Abstract: Plasminogen activators (PA) are obtained from cultured normal human colon cells which are adaptable to large scale production. A purified tissue PA (t-PA) is obtained from CCD-18Co normal human colon fibroblast cells which shows chemical differences from Bowes melanoma t-PA.
    Type: Grant
    Filed: April 9, 1986
    Date of Patent: July 21, 1992
    Assignee: Monsanto Company
    Inventors: Joseph Feder, Nicholaos K. Harakas, Jon P. Schaumann, Daniel T. Connolly, Arthur J. Wittwer
  • Patent number: 5128258
    Abstract: A substantially purified preparation containing one or more soluble Iron-Releasing Monokines and a method of preparing and using same are disclosed. The monokine is heat labile and is retained by ultrafiltration on a YM-10 membrane. Molecular exclusion chromatography of macrophage conditioned supernatant containing the monokine yields fractions in the 30,000 to 65,000 relative molecular weight range with iron-releasing activity. Kinetic studies show that the monokine is rapidly released from activated macrophages after triggering with bacterial endotoxin, reaching plateau levels within 2-4 hours. The response of cells to the monokine depends on both the dose of the monokine administered and the duration of its exposure. The Iron-Releasing Monokine is distinct from other factors secreted by activated macrophages, such as a cytolytic factor and Respiratory Inhibition Factor which causes reversible lesions in the electron transport chain.
    Type: Grant
    Filed: January 7, 1987
    Date of Patent: July 7, 1992
    Assignee: Board of Regents, The University of Texas System
    Inventor: Jim Klostergaard
  • Patent number: 5128245
    Abstract: A stable mutant human megakaryocytic cell line is disclosed which is useful for the study of megakaryocytopoiesis, platelet formation and production, platelet component formation, and the identification and characterization of factors which modulate megakaryocytopoiesis.
    Type: Grant
    Filed: August 17, 1988
    Date of Patent: July 7, 1992
    Assignee: Brigham and Women's Hospital
    Inventors: Sheryl M. Greenberg, Robert I. Handin
  • Patent number: 5128259
    Abstract: Factor-dependent cell line, HU-01, provides the first in vitro system in which human CD34 positive hematopoietic cells have been induced to undergo complete differentiation into enucleated hemoglobin-containing erythrocytes. HU-01 cells may provide a source of monoclonal antibodies useful for early diagnosis and possible treatment of human leukemia conditions, as well as of regulatory factors having therapeutic utility.
    Type: Grant
    Filed: October 27, 1989
    Date of Patent: July 7, 1992
    Assignee: Hahnemann University
    Inventor: Doris A. Morgan
  • Patent number: 5120535
    Abstract: Novel compositions are provided for modulating growth, particularly of tumor cells, which compositions are combinations of Oncostatin M, and one or both of transforming growth factors or .gamma.-interferons, or analogs thereof. In addition, a novel transforming growth factor is provided, designated TGF-.beta.2, as well as methods for its preparation.
    Type: Grant
    Filed: May 4, 1987
    Date of Patent: June 9, 1992
    Assignee: Oncogen
    Inventors: Hans Marquardt, Joyce M. Zarling, Mohammed Shoyab, Marcia B. Hanson, Mario N. Lioubin, Thomas J. Brown, Tatsuhiko Ikeda
  • Patent number: 5112756
    Abstract: Permanent infection of a cell line such as a canine thymus cell line with a retrovirus such as equine infectious anemia virus and bovine Maedi-Visna-like virus is now possible. By culturing such an infected cell line under appropriate conditions, it is now possible to produce large quantities of viral antigens on a continuous basis. Such antigens are useful in for diagnostics and research.
    Type: Grant
    Filed: June 1, 1987
    Date of Patent: May 12, 1992
    Assignee: Canadian Patents and Development Limited
    Inventors: Alain M. P. Bouillant, Klaus Nielsen, Gerda M. Ruckerbauer, Bakhshish S. Samagh, William C. D. Hare
  • Patent number: 5108923
    Abstract: A cell culturing system, methods for the preparation thereof, and methods for affixing other biologically active moieties to a substrate are provided. Said cell culturing system comprises: a substrate; a coating thereon of a sterile formulation comprising polyphenolic protein containing from about 35 to 100% by weight pure bioadhesive polyphenolic protein having the repeating decapeptide unit: ##STR1##wherein N is a whole number ranging from about 10 to about 100, wherein each X is independently selected from the group consisting of hydroxyl and hydrogen, and wherein each R is independently selected from the group consisting of hydrogen and methyl; viable cells affixed to said coated substrate; and a nutritive medium contacting said cells, whereby said cells perform normal metabolic cell functions.
    Type: Grant
    Filed: April 3, 1987
    Date of Patent: April 28, 1992
    Assignee: Collaborative Research, Inc.
    Inventors: Christine V. Benedict, Paul T. Picciano
  • Patent number: 5106743
    Abstract: A method of growing anchorage-dependent cells is disclosed in which a substrate comprising a hydrogel is employed. The hydrogel is formed from an aqueous solution gelled with a crosslinked polymer of a hydrophilic monomer and includes a macromolecule capable of supporting cell growth.
    Type: Grant
    Filed: June 18, 1985
    Date of Patent: April 21, 1992
    Assignee: Trustees of Boston University
    Inventors: Carl Franzblau, Barbara A. Faris, Linda Civerchia-Perez
  • Patent number: 5087565
    Abstract: A process for the production of .sup.32 P-labeled nucleotides in accordance with an enzymatic pathway utilizing phosphotransacetylase and acetate kinase.
    Type: Grant
    Filed: July 2, 1984
    Date of Patent: February 11, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: James J. Di Meo
  • Patent number: 5079160
    Abstract: A method to obtain purified, well-defined cell populations from intact organs uses digestion of the distended organ with suitable proteolytic enzymes and harvest of the cell subpopulation by screening the effluent from treatment of the organ with physiologically compatible medium by a filtration screen permitting the passage of the desired cells or clusters of cells, but preventing the passage of larger particles. In this manner, physical/mechanical disruption of the cell population is unnecessary, and the cells or clusters are eased out of their structural matrix and harvested directly. Application of this method to the preparation of purified Islets of Langerhans from intact pancreas is described.
    Type: Grant
    Filed: June 8, 1987
    Date of Patent: January 7, 1992
    Inventors: Paul E. Lacy, David W. Scharp, Camillo Ricordi
  • Patent number: 5075224
    Abstract: DNA encoding a novel polypeptide hormone, designated CTP, has been identified in the human genome. CTP is expressed as a fusion protein (proLHRH) with luteinizing hormone releasing hormone (LHRH), and is post-translationally processed to CTP and LHRH. CTP, its derivatives, and its fusions, including proLHRH, are useful in therapy and diagnostics.
    Type: Grant
    Filed: April 2, 1991
    Date of Patent: December 24, 1991
    Assignee: Genentech, Inc.
    Inventors: Peter H. Seeburg, John P. Adelman
  • Patent number: 5073492
    Abstract: A method for synergistically enhancing endothelial cell growth in an appropriate environment therefor which comprises adding to the environment, VEGF, effectors and serum-derived factor. A formulation for synergistically enhancing endothelial cell growth comprising VEGF, uridine, thymidine and serum-derived factor is also disclosed.
    Type: Grant
    Filed: January 9, 1987
    Date of Patent: December 17, 1991
    Assignee: The Johns Hopkins University
    Inventors: Chung-Ho Chen, Sumi C. Chen
  • Patent number: 5061629
    Abstract: Enantiomerically pure (2R)-2-hydroxy arylalkanoic acid esters and (2S)-2-hydroxy arylalkanoic acids are prepared by the Pseudomonas lipase-catalyzed selective hydrolyxis of racemic (2RS)-2-hydroxy arylalkanoic acid esters in solution or suspension in an aqueous medium at a controlled pH of from about 5 to about 9.
    Type: Grant
    Filed: October 29, 1990
    Date of Patent: October 29, 1991
    Assignee: Hoffman-La Roche Inc.
    Inventors: David L. Coffen, Panayiotis Kalaritis, John J. Patridge
  • Patent number: 5057423
    Abstract: A method for the preparation of LAK-active lymphocytes; a method of immunotherapy utilizing these LAK-active lymphocytes, relatively homogeneous compositions of large granular lymphocytes, and relatively homogeneous compositions of LAK-active lymphocytes.
    Type: Grant
    Filed: December 18, 1987
    Date of Patent: October 15, 1991
    Assignee: University of Pittsburgh
    Inventors: John C. Hiserodt, Nikola L. Vujanovic
  • Patent number: 5049497
    Abstract: The enantiomers of formulas ##STR1## are prepared in a sequence starting from the racemic compound of formula ##STR2## wherein X is hydro or bromo when Y is bromo, or X is chloro when Y is chloro. The key step of this process involves a microbial reduction of the compound of formula (3) to give a ketone and an alcohol of high enantiomeric purity.
    Type: Grant
    Filed: August 25, 1986
    Date of Patent: September 17, 1991
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Arthur F. Kluge, Dennis J. Kertesz
  • Patent number: 5037747
    Abstract: Enantiomerically pure (2R)-hydroxy-substituted benzopyran-2-carboxylic acid esters and (2S)-hydroxy-substituted benzopyran-2-carboxylic acids, are prepared by the Pseudomonas lipase-catalyzed selective hydrolysis of racemic (2RS)-hydroxy-substituted benzopyran-2-carboxylic acid esters in solution or suspension in an aqueous or aqueous/organic medium, at a pH of from about 5 to about 10.
    Type: Grant
    Filed: January 26, 1988
    Date of Patent: August 6, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David L. Coffen, Panayiotis Kalaritis, John J. Partridge
  • Patent number: 5037741
    Abstract: The present invention provides a method for the enzymatic synthesis of peptides accomplished by shifting the chemical equilibrium that exists in a reaction mixture between charged or ionized reacting amino acids and uncharged or non-ionized peptide product in the presence of a proteolytic enzyme such as thermolysin. The equilibrium is shifted by diffusion of the uncharged peptide product across an ion-rejection membrane which removes the uncharged peptide from the reaction mixture and preferably the diffused uncharged peptide is quickly converted to a charged species that cannot back-diffuse into the reaction mixture so that the uncharged peptide is effectively "pulled" across the membrane.
    Type: Grant
    Filed: August 18, 1986
    Date of Patent: August 6, 1991
    Assignee: The Coca Cola Company
    Inventor: Guillermo A. Iacobucci
  • Patent number: 5036009
    Abstract: The production of 1,2-dihydroxy-cyclohexadienes from aromatic compounds by a biochemical process by using strains of Pseudomonas putida, and novel 1,2-disubstituted-cyclo-hexadienes are described. Certain of the novel compounds are useful as intermediates in the production of polymers.
    Type: Grant
    Filed: December 31, 1984
    Date of Patent: July 30, 1991
    Assignee: Imperial Chemical Industries PLC
    Inventor: Stephen C. Taylor
  • Patent number: RE33772
    Abstract: The invention relates to live deletion mutants of a herpesvirus, especially of Pseudorabies virus. The genomes of the mutants differ from the genomes of the parent strain by the presence of one or more deletions selected from a deletion in the inverted repeats, a deletion in the unique sequence, and a deletion in the thymidine kinase gene.The new deletion mutants are avirulent, do not induce latent infections, are stable and possess good immunogenic properties.The invention also relates to vaccines containing the new mutant strains.
    Type: Grant
    Filed: August 2, 1988
    Date of Patent: December 17, 1991
    Assignee: Centraal Diergeneeskundig Instituut
    Inventors: Antonius J. M. Berns, Arnold L. J. Gielkens